

Press Release

AP-HP, the Paris Public Hospitals Group, and Magnisense sign a partnership agreement to develop emergency diagnostic tests for cardiovascular diseases

Paris, September 25, 2014 – AP-HP, the Paris Public Hospitals Group (*Assistance Publique–Hôpitaux de Paris*), and the company Magnisense have signed a partnership agreement to develop emergency diagnostic tests for cardiovascular diseases. Under this partnership, AP-HP provides Magnisense with precious and unique biological samples from cohorts of patients suffering from cardiovascular diseases and participates in validating tests. AP-HP also grants Magnisense a license option agreement for the global and exclusive commercial exploitation of one of its patents on postpartum hemorrhage in women. AP-HP's Office of Technology Transfer, Licensing & Industrial Ventures, in charge of filing patent applications and promoting the innovations of AP-HP, has drawn up the agreements, which set out the terms of the partnership and license option agreement for commercial exploitation between AP-HP and Magnisense.

Magnisense and the team of Professor Alexandre Mebazaa and Doctor Etienne Gayat (Anesthesia and Reanimation Department, Lariboisière Hospital) are working together to develop and record proprietary emergency diagnostic tests for myocardial infarction that meet the requirements of hospital emergency physicians, reanimation specialists, anesthesiologists and cardiologists. These quantitative tests are based on whole blood, take 15 minutes and are robust, portable, economical and WiFi-enabled. The instrument designed by Magnisense based on its proprietary MIAtek® technology is used to conduct the tests. Magnisense aims to commercialize its first diagnostic tests in France within the next few months, then in Europe and the rest of the world.

These same tests can also be recorded and commercialized to “predict postpartum hemorrhage in women”, one of the most common causes of death after childbirth. The tests, which contribute in establishing a predictive score for the risk of postpartum hemorrhage – as demonstrated by the innovative work of Prof. Mebazaa and Dr. Gayat*, patented and validated in two cohorts of patients – will be developed through the option license agreement for commercial exploitation granted by AP-HP to Magnisense.

“The development of reliable, inexpensive and easy-to-use point-of-care tools for biological measurement meets a real need. Biomarkers are now used on a day-to-day basis, both to help in diagnosis and stratify risk as well as to guide the treatment of the patients that we care for every day, in particular patients at high cardiovascular risk,” explains Prof. Alexandre Mebazaa, Head of the Anesthesia and Reanimation Department at the Saint-Louis-Lariboisière Hospital Group.

“Our proprietary emergency diagnostic tests for cardiovascular diseases offer a concrete response to major public health and economic concerns throughout the world. We are delighted about this partnership with Professor Alexandre Mebazaa’s team and AP-HP. It

enables Magnisense to ensure the safety of the development and validation quality of its tests,”
adds Lyse Santoro, Chief Executive Officer of Magnisense.

* *“Novel method of prognosis associated with cases of postpartum hemorrhage”, Patent WO2010015690 A1*
(inventors: A. Mebazaa, E. Gayat, M. Resche Rigon, M. Rossignol, O. Morel, Y. Fargeaudou and D. Payen).

AP-HP, the Paris Public Hospitals Group (Assistance Publique Hôpitaux de Paris), is the Paris area’s University Medical Center (UMC) and the leading UMC in Europe. With 37 hospitals, divided into 12 hospital groups and one federation for multiple disabilities, AP-HP works with the other regional healthcare players. Our ambition is to provide a quality medical offering in line with the needs of the local population. AP-HP also mobilizes its full expertise and innovative capabilities to the benefit of patients with complex pathologies. AP-HP’s Office of Technology Transfer, Licensing & Industrial Ventures is responsible for protecting and leveraging the innovations and clinical expertise of AP-HP’s medical staff by establishing close partnerships with healthcare companies to share the challenge of competitiveness and development. AP-HP is a healthcare leader, with a vast portfolio of over 500 patents, databases and unique biological material. Nearly half of the patented innovations have been licensed to companies throughout the world or the catalyst for setting up nearly 60 young companies. Every year, AP-HP organizes the APInnov Tech Transfer Event to bring AP-HP projects in contact with industrial groups. www.aphp.fr

About Magnisense: Magnisense designs, develops and commercializes emergency diagnostic tests for cardiovascular diseases using its MIAtek® technology and its proprietary instrument. The MIAtek®, featuring groundbreaking technology using magnetic nanoparticles, is protected by five families of patents issued in Europe and the United States. Magnisense was founded by the inventor of the technology and a group of business angels. The main investors are Daniel Bernard and Jean-Patrick Voisin. Its head office is in Paris, and its R&D laboratory, “Le Campus”, is located in the Lyon Biopôle. Magnisense aims to become a leader in emergency cardiac diagnosis by commercializing competitive tests that address healthcare and economic issues. <https://www.youtube.com/watch?v=Yjmegpsajw0>

About cardiovascular diseases: Cardiovascular diseases are the leading cause of death worldwide, killing 17 million people every year. As the population ages, this figure is expected to reach 24 million by 2030. Given the sharp increase in cardiovascular accidents and the associated direct and indirect costs, a genuine medical need has developed for rapid, robust, portable and economical emergency diagnostic tests.

Press contacts:

AP-HP: service.presse@sap.aphp.fr – Tel.: +33 (0)1 40 27 37 22

Magnisense: info@magnisense.com – Tel.: +33 (0)1 45 62 80 00

Alize RP : Caroline Carmagnol caroline@alizerp.com – Tel.: +33 (0)1 70 22 53 90 / Sophie Colin scolin@alizerp.com – Tel.: +33 (0)1 70 22 53 93